CRISPR Therapeutics Stock News

Genomics is undeniably medicine's future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature.

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

CRISPR Therapeutics is blazing new trails in the promising area of gene editing. Block's two central ecosystems and several other ventures promise a bright future.

CRISPR Therapeutics and Vertex Pharmaceuticals just launched a gene therapy. For now, it's a pricey medicine, and there aren't many eligible patients.

The main reason to consider buying CRISPR Therapeutics has little to do with its newly approved gene-editing therapy. Instead, the biotech's promising pipeline is the key factor that should be attract

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Adm

CRISPR Therapeutics now has an approved product in its portfolio in Casgevy. The treatment has the potential to be a game changer for the company's business.

CRISPR Therapeutics won regulatory approval of its first product, Casgevy, for blood disorders. This is also the world's first approval of a treatment based on CRISPR gene editing.

Small-cap stocks are often overlooked yet they can provide investors with significant potential for outperformance. That said, not all small-cap stocks are worth considering.

Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Dru

Intellia and CRISPR Therapeutics both work in the field of gene editing. CRISPR Therapeutics just won regulatory approval for its first product, while Intellia recently entered late-stage development

Samarth Kulkarni, CRISPR Therapeutics CEO, joins 'Closing Bell Overtime' to talk winning FDA approval in the U.S. for sickle cell treatment in partnership with Vertex.

2023: Predicting is Futile, Interpreting is Priceless

Crispr Therapeutics AG ( NASDAQ:CRSP) stock is down 7.2% to trade at $59.89 at last check, despite its gene therapy treatment for sickle cell disease in partnership with Vertex (VRTX) last week recei